Sign up to save your podcasts
Or
Share Foundayo GLP-1 Pill: FDA Needs More Data
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Foundayo GLP-1 Pill: FDA Needs More Data
Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use.
Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.
View all episodes
By Dave Knapp GLP-1 Industry Insider
4.9
351351 ratings
Orforglipron (also known as Foundayo) is one of the most promising drugs in the GLP-1 space, notably as only the second oral GLP-1 option for obesity. Unlike injectable treatments, it does not require refrigeration and is easier to scale for widespread use.
Dave highlights the ongoing questions that linger about the drugs approval as it relates to liver safety.
More shows like On The Pen GLP-1 News
View all
The Hormone Solution | Menopause, Perimenopause, & Women's Midlife Health
342 Listeners
Everyday Wellness: Midlife Hormones, Menopause, and Science for Women 35+
150 Listeners
The Holistic GLP-1 Podcast with Elizabeth McGann
64 Listeners
The Hunter Williams Podcast
121 Listeners
The Dr. Tyna Show
1,685 Listeners
Docs Who Lift
422 Listeners
The Obesity Guide with Matthea Rentea MD
267 Listeners
The Plus SideZ: A GLP-1 Guide to Metabolic Health
219 Listeners
Your GLP-1 Bestie
34 Listeners
The Peptide Podcast
102 Listeners
Fat Science
171 Listeners
West Wellness & Longevity
41 Listeners
GLP-1 Hub: Support, Community, and Weight Loss
160 Listeners
GLP-1 Tribe
44 Listeners
Today's discussion on unraveling BPC 157 Peptide
20 Listeners